Journal of Clinical Endocrinology & Metabolism, Vol 81, 2419-2422, Copyright © 1996 by Endocrine Society

ARTICLES

Tibolone: prevention of bone loss in late postmenopausal women

NH Bjarnason, K Bjarnason, J Haarbo, C Rosenquist and C Christiansen
Center for Clinical and Basic Research, Ballerup, Denmark.

The aim of the study was to assess the effects of 2 yr of treatment with two dose levels of tibolone on bone mineral density and bio- chemical markers of bone metabolism in late postmenopause. Ninety-one healthy women, more than 10 yr after menopause, entered a 2-yr double blind, randomized, placebo-controlled study of treatment with either 1.25 mg/day (n = 36) or 2.5 mg/day (n = 35) Tibolone or placebo (n = 20). Densitometry and determinations of biochemical markers of bone metabolism in serum and urine were performed before randomization and every 3 months during the study. The results revealed a steady and equal increase in bone mineral density in both tibolone groups at the bone sites studied. Gains in BMD spine of 5.9 +/- 0.9% in the 1.25 mg group, 5.1 +/- 0.9% in the 2.5 mg group, and 0.4 +/- 1.1% in the placebo group were found. In the forearm, increases of 2.2 +/- 0.7% in the 1.25 mg group and 1.9 +/- 1.1% in the 2.5 mg group were detected, whereas the placebo group lost 2.1 +/- 1.0%. This was fully supported by changes in biochemical markers of bone resorption (urinary excretion of fragments from the osteoclastic degradation of the alpha 1-chain of the C telopeptides of type 1 collagen and hydroxyproline) and bone formation (serum osteocalcin), respectively. In conclusion, within 2 yr of treatment, tibolone increases bone mass in the spine and prevents bone loss in the forearm in late postmenopausal women determined by densitometry and several biochemical parameters of bone turnover. Tibolone at two doses (1.25 and 2.5 mg/day) had similar effects, indicating that even lower doses may be efficacious.

This article has been cited by other articles:

				S. R. Cummings, B. Ettinger, P. D. Delmas, P. Kenemans, V. Stathopoulos, P. Verweij, M. Mol-Arts, L. Kloosterboer, L. Mosca, C. Christiansen, et al. The Effects of Tibolone in Older Postmenopausal Women N. Engl. J. Med., August 14, 2008; 359(7): 697 - 708. [Abstract] [Full Text] [PDF]

				J. M Swegle and M. W Kelly Tibolone: A Unique Version of Hormone Replacement Therapy Ann. Pharmacother., May 1, 2004; 38(5): 874 - 881. [Abstract] [Full Text] [PDF]

				M. Doren, J.-A. Nilsson, and O. Johnell Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis Hum. Reprod., August 1, 2003; 18(8): 1737 - 1746. [Abstract] [Full Text] [PDF]

				E Dogan and C Posaci Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women Postgrad. Med. J., December 1, 2002; 78(926): 727 - 731. [Abstract] [Full Text] [PDF]

				T. B. Clarkson, M. S. Anthony, T. S. Mikkola, and R. W. St Clair Comparison of Tibolone and Conjugated Equine Estrogens Effects on Carotid Artery Atherosclerosis of Postmenopausal Monkeys Stroke, November 1, 2002; 33(11): 2700 - 2703. [Abstract] [Full Text] [PDF]

				P. Garnero, C. Jamin, C.-L. Benhamou, C. Pelissier, and C. Roux Effects of tibolone and combined 17{beta}-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial Hum. Reprod., October 1, 2002; 17(10): 2748 - 2753. [Abstract] [Full Text] [PDF]

				T. S Mikkola and T. B Clarkson Estrogen replacement therapy, atherosclerosis, and vascular function Cardiovasc Res, February 15, 2002; 53(3): 605 - 619. [Abstract] [Full Text] [PDF]

				K. Modelska and S. Cummings Tibolone for Postmenopausal Women: Systematic Review of Randomized Trials J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 16 - 23. [Abstract] [Full Text] [PDF]

				T. B. Clarkson, M. S. Anthony, and J. D. Wagner A Comparison of Tibolone and Conjugated Equine Estrogens Effects on Coronary Artery Atherosclerosis and Bone Density of Postmenopausal Monkeys J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5396 - 5404. [Abstract] [Full Text] [PDF]

				J. C. Gallagher, D. J. Baylink, R. Freeman, and M. McClung Prevention of Bone Loss with Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4717 - 4726. [Abstract] [Full Text] [PDF]

				S. Palacios Tibolone: a tissue-specific approach to the menopause Eur. Heart J. Suppl., October 1, 2001; 3(suppl_M): M12 - M16. [Abstract] [PDF]

				P. Zandberg, J. L. M. Peters, P. N. M. Demacker, M. J. Smit, E. G. de Reeder, and D. G. Meuleman Tibolone Prevents Atherosclerotic Lesion Formation in Cholesterol-Fed, Ovariectomized Rabbits Arterioscler. Thromb. Vasc. Biol., December 1, 1998; 18(12): 1844 - 1854. [Abstract] [Full Text] [PDF]

				S. Christgau, C. Rosenquist, P. Alexandersen, N. H. Bjarnason, P. Ravn, C. Fledelius, C. Herling, P. Qvist, and C. Christiansen Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides Clin. Chem., November 1, 1998; 44(11): 2290 - 2300. [Abstract] [Full Text] [PDF]

				N. H. Bjarnason, K. Bjarnason, J. Haarbo, H. J.T. C. Bennink, and C. Christiansen Tibolone: Influence on Markers of Cardiovascular Disease J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1752 - 1756. [Abstract] [Full Text] [PDF]